New breast cancer drug copy tested in major trial
NCT ID NCT06038539
Summary
This study aimed to see if a new, similar version of the cancer drug pertuzumab (called PERT-IJS) works as well and is as safe as the original drug (EU-Perjeta) when given before surgery. It involved 55 women with a specific type of early or locally advanced breast cancer (HR-negative, HER2-positive). The trial was designed to compare how well the two drug versions, when combined with other standard treatments, could eliminate cancer from the breast and lymph nodes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR NEGATIVE HER2 POSITIVE EARLY BREAST CANCER OR LOCALLY ADVANCED BREAST CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chopda Medicare & Research Centre Pvt. Ltd,
Nashik, 422005, India
Conditions
Explore the condition pages connected to this study.